Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET over exp |
| Therapy | Cabozantinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET over exp | Advanced Solid Tumor | predicted - sensitive | Cabozantinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) treatment resulted in moderate tumor volume reduction in a cell line xenograft model of transformed cells overexpressing RET (PMID: 30446652). | 30446652 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (30446652) | RET rearrangements are actionable alterations in breast cancer. | Full reference... |